Skip to main content
SpringerLink
Log in

Aktuelle Therapiestrategien beim Neuroblastom

Current therapy strategies for neuroblastoma

  • Leitthema
  • Published:
Monatsschrift Kinderheilkunde Aims and scope Submit manuscript

Zusammenfassung

Das Neuroblastom ist der häufigste extrakraniale solide Tumor des Kindesalters. Je nach seiner Lokalisation kommt es zu den für Neuroblastome charakteristischen, aber lageabhängigen Symptomen. Ein 123I-MIBG-Scan ist das Standarddiagnoseverfahren der Wahl für alle Tumorlokalisationen. Ebenso sind beidseitig gewonnene Markaspirate der hinteren Darmbeinschaufelleiste und Biopsien des Knochenmarkkerns unverzichtbar. Entscheidender Marker für die Beurteilung der Dignität von neuroblastischen Tumoren ist die MYCN-Onkogen-Amplifikation. Das Neuroblastom muss risikoadaptiert behandelt werden. Aus diesem Grund sind eine entsprechend exakte Diagnostik und Klassifikation unverzichtbar, und die Therapie soll an dafür spezialisierten Zentren und im Rahmen von qualitätssichernden Therapieoptimierungsstudien durchgeführt werden.

Abstract

Neuroblastoma is the most common form of extracranial solid tumor in childhood. Depending on the localization neuroblastomas result in characteristic but site-dependent symptoms. An iodine-123-meta-iodobenzylguanidine (MIBG) scan is the standard diagnostic procedure of choice for all tumor localizations. Bilateral marrow aspirates from the posterior iliac crest and biopsies of bone marrow are also indispensible. The decisive marker for assessment of dignity of neuroblastomas is MYCN oncogene amplification. Neuroblastomas must be treated in a risk-adapted manner. For this reason exact diagnostics and classification are indispensible and the therapy should be carried out in specialized centers within the framework of quality assured therapy optimization studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Ambros IM, Zellner A, Roald B et al (1996) Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma. N Engl J Med 334:1505–1511

    Article  CAS  PubMed  Google Scholar 

  2. Berthold F, Hero B, Kremens B et al (2003) Long-term results and risk profiles of patients in five consecutive trials (1979–1997) with stage 4 neuroblastoma over 1 year of age. Cancer Lett 197(1–2):11–17

    Article  CAS  PubMed  Google Scholar 

  3. Brodeur GM, Pritchard J, Berthold F et al (1993) Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11(8):1466–1477

    Article  CAS  PubMed  Google Scholar 

  4. Cohn SL, Pearson AD, London WB et al (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27:289–297

    Article  PubMed  PubMed Central  Google Scholar 

  5. Hero B, Simon T, Spitz R et al (2008) Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 26(9):1504–1510

    Article  PubMed  Google Scholar 

  6. Ladenstein R, Berthold F, Ambros I, Ambros P (2006) Neuroblastome. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J (Hrsg) Pädiatrische Hämatologie und Onkologie. Springer, Berlin Heidelberg New York, S 829–846

  7. Ladenstein R, Poetschger U, Luksch R et al (2011) Busulphan-melphalan is the superior myeloablative therapy (MAT) for high risk neuroblastoma: Results from the HR-NBL1/SIOPEN trial. ASCO 2011/Abstract #79897

  8. Matthay KK, Reynolds CP, Seeger RC et al (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 27:1007–1013

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Matthay KK, George RE, Yu AL (2012) Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18(10):2740–2753

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Monclair T, Brodeur GM, Ambros PF et al (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol 27:298–303

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mossé YP, Laudenslager M, Longo L et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215):930–935

    Article  PubMed  PubMed Central  Google Scholar 

  12. Mossé YP, Wood A, Maris JM (2009) Inhibition of ALK signaling for cancer therapy. Clin Cancer Res 15(18):5609–5614

    Article  PubMed  Google Scholar 

  13. Shimada H, Ambros IM, Dehner LP et al (1999) The international neuroblastoma pathology classification (INPC) (the Shimada system). Cancer 86:364–372

    Article  CAS  PubMed  Google Scholar 

  14. Simon T, Hero B, Faldum A et al (2011) Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. BMC Cancer.11:21

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yu AL, Gilman AL, Ozkaynak MF, London WB et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324–1334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Interessenkonflikt

Die korrespondierende Autorin gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. St. Anna Kinderkrebsforschung e. V., Zimmermannplatz 10, A-1090, Wien, Österreich

    R. Ladenstein

Authors
  1. R. Ladenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Ladenstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ladenstein, R. Aktuelle Therapiestrategien beim Neuroblastom. Monatsschr Kinderheilkd 160, 947–957 (2012). https://doi.org/10.1007/s00112-012-2690-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00112-012-2690-9

Schlüsselwörter

Keywords

Search

Navigation